# A Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors

Source: https://onco.cc/trials/nct05142423/  
OnCo record `nct05142423` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of AK109+AK104 in advanced solid tumours, run by Akeso, now recruiting.

## Summary

A Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05142423 by Akeso, with 198 participants planned, started 2021-11-03 and due to reach its primary completion in 2027-04. Interventions recorded: AK109+AK104.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05142423
- Phase: 1/2
- Setting: An Open Label, Multi-center, Phase Ib/II Clinical Study of AK109 Combined With AK104 to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity in Advanced Solid Tumors
- Sponsor: Akeso
- Enrolled: 198

## Sources

- ClinicalTrials.gov NCT05142423: https://clinicaltrials.gov/study/NCT05142423

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Akeso](https://onco.cc/companies/akeso/)

---
JSON: https://onco.cc/api/v1/entities/nct05142423.json